Brain Somatic Variant in Ras-Like Small GTPase RALA Causes Focal Cortical Dysplasia Type II

Area of Science:

• Neuroscience
• Genetics
• Molecular Biology

Background:

• Focal Cortical Dysplasia type II (FCD II) is a significant cause of drug-resistant epilepsy in children.
• The genetic underpinnings of FCD II, particularly somatic mutations, are not fully understood.
• Previous studies identified a somatic RALA variant in FCD II brain tissue, but its role was unknown.

Purpose of the Study:

• To investigate the role of the somatic RALA variant in the pathogenesis of FCD II.
• To elucidate the molecular mechanisms by which RALA mutations affect brain development.
• To determine if RALA mutations activate the mammalian target of rapamycin (mTOR) pathway.

Main Methods:

• In vitro analysis of RalA protein expression, mTOR pathway activation (P-S6), and RalA GTPase activity in transfected HEK293T cells.
• In vivo studies using in utero electroporation in mice to assess the impact of RALA c.G482A on neuronal migration.
• Analysis of RalA interaction with downstream binding effectors.

Main Results:

• The RALA c.G482A mutation led to increased RalA protein expression and abnormal activation of the mTOR pathway.
• Mutant RALA enhanced RalA GTPase activity and its binding to downstream effectors.
• In utero transfection of RALA c.G482A in mouse embryos resulted in disrupted cortical neuron migration.

Conclusions:

• Somatic gain-of-function mutations in RALA activate the mTOR pathway, leading to neuronal migration disorders and contributing to FCD II.
• RALA somatic mutations represent a potential pathogenic mechanism for FCD II and associated drug-resistant epilepsy.
• Further validation in larger patient cohorts is needed to confirm the role of RALA variations in FCD II.